FDA Liposome Drug Products Draft Guidance Expected By Year-End
FDA expects to issue a draft guidance on chemistry, manufacturing and control issues in the production of liposome drug products by the end of the year.
You may also be interested in...
Dosing for liposome drug products could be determined through comparative pharmacokinetic studies of liposomal and nonliposomal products containing the same active moiety, an FDA draft guidance says
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011